First SARS-CoV-2 Exposure Shapes IgG Subclass Switching and Breakthrough Infection Risk After mRNA Vaccination
核心洞察
Repeated mRNA vaccination induces a sustained IgG4 (搜索) class switch that persists across at least six doses, primarily in individuals naïve to SARS-CoV-2 (搜索) at first vaccination.
An IgG4 (搜索)-dominated signature was associated with increased risk of breakthrough infection (HR = 1.83, p = 0.028) in infection-naïve adults lacking mucosal IgA responses.
First exposure history critically shapes antibody quality: infection before vaccination limits IgG2 (搜索)/IgG4 (搜索) switching, while infection after vaccination does not.
Two complementary studies published in Nature journals reveal that an individual's first exposure to SARS-CoV-2 (搜索)—whether through infection or vaccination—profoundly shapes the quality and subclass distribution of antibody responses following repeated mRNA vaccination, with implications for breakthrough infection risk.
A Swedish study, utilizing a liquid chromatography–mass spectrometry-based approach, characterized spike-specific IgG responses across six mRNA vaccine doses in a healthcare worker cohort (n = 104) and across three doses in a Singaporean pediatric cohort (n = 18). The research demonstrated that repeated mRNA vaccination induced an IgG4 (搜索) class switch that was sustained across at least six doses.
IgG4 (搜索) Class Switch and Breakthrough Infection Risk
The IgG4 (搜索)-dominated immunological signature was associated with an increased risk of breakthrough infection (HR = 1.83, p = 0.028) in infection-naïve individuals (n = 41) who lacked mucosal IgA responses. The researchers noted that mucosal IgA absence was important for interpretation, as its presence could potentially confound the assessment of systemic IgG4-related infection outcomes.
"The IgG4 (搜索) class switch was preceded with high early IgG1 Fc fucosylation signatures," the authors reported, identifying a potential early biomarker for subsequent subclass switching. Notably, these IgG structural changes were observed primarily in individuals who were naïve to SARS-CoV-2 (搜索) at the time of first vaccination. Similar IgG structural features were also documented across three mRNA doses in the small infection-naïve pediatric cohort.
Exposure History as a Critical Determinant
A parallel study conducted in a Spanish healthcare worker cohort reinforced and extended these findings by analyzing IgG1–4 subclasses, C1q, and FcγR (搜索)-binding IgG against antigens from multiple SARS-CoV-2 (搜索) variants. The results indicated that subclass responses are shaped by exposure history, with infection before vaccination limiting the extent of IgG2 (搜索) and IgG4 (搜索) class switching relative to infection after vaccination.
"IgG4 (搜索) exhibits broader reactivity to Omicron variants than IgG1, and both IgG2 (搜索) and IgG4 show slower decay of circulating antibody levels than IgG1," the Spanish team found. This greater durability of IgG2 and IgG4, however, did not translate into enhanced protection. During Omicron predominance, elevated IgG2 and IgG4 were linked to increased risk of breakthrough infection in vaccinees, whereas levels of IgG1 and FcγR (搜索)- and C1q-binding antibodies were associated with protection.
Functional Competition Between Subclasses
The Spanish study also uncovered evidence of competition between antibody subclasses. IgG4 (搜索) levels correlated with FcγR (搜索)- and C1q-binding antibodies only in participants with lower IgG1, suggesting that IgG4 may compete with IgG1 for antigen binding, potentially reducing the functional capacity of the overall antibody response.
Implications for Future Vaccine Design
Both research groups emphasized that their findings do not call into question the efficacy or safety of the widely adapted mRNA vaccine platform. However, the results suggest that future vaccines may need to consider antibody quality—not just quantity—to improve long-term protection.
"These findings suggest that not all antibodies work the same way, and future vaccines may need to consider antibody quality, not just quantity, to improve long-term protection," the Spanish researchers concluded. The Swedish team similarly stated that while their results "do not call into question the efficacy or safety of the widely adapted mRNA vaccine platform, they may have implications that merit further investigation."
The studies collectively highlight that immune priming by prior infection may shape subsequent mRNA vaccine-induced antibody responses in ways that influence protective immunity, and further studies are warranted to clarify the mechanistic and clinical implications of IgG subclass shift for long-term protection.